Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Morère J[au]:

Current and Former Smokers: Who Wants To Be Screened? Couraud S et al. Clin Lung Cancer. (2018)

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. Couraud S et al. Prev Med Rep. (2018)

[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys]. Eisinger F et al. Bull Cancer. (2017)

Search results

Items: 1 to 50 of 174

1.

The day after: correlates of patient-reported outcomes with actigraphy-assessed sleep in cancer patients at home (inCASA project).

Komarzynski S, Huang Q, Lévi FA, Palesh OG, Ulusakarya A, Bouchahda M, Haydar M, Wreglesworth NI, Morère JF, Adam R, Innominato PF.

Sleep. 2019 Oct 9;42(10). pii: zsz146. doi: 10.1093/sleep/zsz146.

PMID:
31323086
2.

Analysis of the 4q35 chromatin organization reveals distinct long-range interactions in patients affected with Facio-Scapulo-Humeral Dystrophy.

Gaillard MC, Broucqsault N, Morere J, Laberthonnière C, Dion C, Badja C, Roche S, Nguyen K, Magdinier F, Robin JD.

Sci Rep. 2019 Jul 17;9(1):10327. doi: 10.1038/s41598-019-46861-x.

3.

Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.

Ulusakarya A, Teyar N, Karaboué A, Haydar M, Krimi S, Biondani P, Gumus Y, Chebib A, Almohamad W, Morère JF.

Medicine (Baltimore). 2019 Apr;98(16):e15341. doi: 10.1097/MD.0000000000015341.

4.

Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection.

Ruiz A, Sebagh M, Saffroy R, Allard MA, Bosselut N, Hardoin G, Vasseur J, Hamelin J, Adam R, Morère JF, Lemoine A.

BMC Cancer. 2019 Feb 22;19(1):169. doi: 10.1186/s12885-019-5365-2.

5.

Current and Former Smokers: Who Wants To Be Screened?

Couraud S, Greillier L, Brignoli-Guibaudet L, Lhomel C, Viguier J, Morère JF, Eisinger F, Cortot AB.

Clin Lung Cancer. 2018 Nov;19(6):493-501. doi: 10.1016/j.cllc.2018.07.001. Epub 2018 Jul 6.

PMID:
30107977
6.

Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey.

Couraud S, Cortot AB, Pivot XB, Touboul C, Lhomel C, Blay JY, Eisinger F, Viguier J, Morère JF, Greillier L.

Prev Med Rep. 2018 Apr 18;10:332-336. doi: 10.1016/j.pmedr.2018.04.009. eCollection 2018 Jun.

7.

Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison.

Ruiz A, van Hillegersberg R, Siesling S, Castro-Benitez C, Sebagh M, Wicherts DA, de Ligt KM, Goense L, Giacchetti S, Castaing D, Morère J, Adam R.

Eur J Cancer. 2018 May;95:1-10. doi: 10.1016/j.ejca.2018.02.024. Epub 2018 Mar 23.

PMID:
29579478
8.

Colon Cancer Screening Programs: Impact of an Organized Screening Strategy Assessed by the EDIFICE Surveys.

Viguier J, Morère JF, Brignoli-Guibaudet L, Lhomel C, Couraud S, Eisinger F.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):16. doi: 10.1007/s11912-017-0648-8.

PMID:
29508157
9.

Awareness and Misconceptions of Breast Cancer Risk Factors Among Laypersons and Physicians.

Morère JF, Viguier J, Couraud S, Brignoli-Guibaudet L, Lhomel C, Pivot XB, Eisinger F.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):15. doi: 10.1007/s11912-017-0647-9.

PMID:
29508148
10.

Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey.

Viguier J, Morère JF, Pivot X, Touboul C, Lhomel C, Couraud S, de La Motte Rouge T, Eisinger F.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):14. doi: 10.1007/s11912-017-0646-x.

PMID:
29508088
11.

Perception of Lung Cancer Risk: Impact of Smoking Status and Nicotine Dependence.

Greillier L, Cortot AB, Viguier J, Brignoli-Guibaudet L, Lhomel C, Eisinger F, Morère JF, Couraud S.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):18. doi: 10.1007/s11912-017-0650-1.

PMID:
29508085
12.

Decline in Cancer Screening in Vulnerable Populations? Results of the EDIFICE Surveys.

Morère JF, Eisinger F, Touboul C, Lhomel C, Couraud S, Viguier J.

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):17. doi: 10.1007/s11912-017-0649-7.

PMID:
29508084
13.

Long-term survival and cure model following liver resection for breast cancer metastases.

Ruiz A, Sebagh M, Wicherts DA, Castro-Benitez C, van Hillegersberg R, Paule B, Castaing D, Vibert E, Cunha AS, Cherqui D, Morère JF, Adam R.

Breast Cancer Res Treat. 2018 Jul;170(1):89-100. doi: 10.1007/s10549-018-4714-1. Epub 2018 Feb 20.

14.

Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians.

Saffroy R, Morère JF, Bosselut N, Innominato PF, Hamelin J, Trédaniel J, Masse S, Dussaule-Duchatelle V, Balaton A, Validire P, Guettier C, Bouchahda M, Lemoine A.

Oncotarget. 2017 Feb 7;8(31):50792-50803. doi: 10.18632/oncotarget.15132. eCollection 2017 Aug 1.

15.

Is Cure Possible After Sequential Resection of Hepatic and Pulmonary Metastases From Colorectal Cancer?

Rajakannu M, Magdeleinat P, Vibert E, Ciacio O, Pittau G, Innominato P, SaCunha A, Cherqui D, Morère JF, Castaing D, Adam R.

Clin Colorectal Cancer. 2018 Mar;17(1):41-49. doi: 10.1016/j.clcc.2017.06.006. Epub 2017 Jun 23.

PMID:
28709876
16.

Factors influencing colorectal cancer screening participation rates in 2016.

Viguier J, Morere JF, Pivot X, Cortot AB, Blay JY, Touboul C, Lhomel C, Greillier L, Couraud S, Eisinger F.

Ann Oncol. 2017 Jun;28 Suppl 3:iii90-iii91. doi: 10.1093/annonc/mdx261.256. No abstract available.

17.

[Cancer screening in France: 10 years of analysis of behaviours by the EDIFICE surveys].

Eisinger F, Pivot X, Greillier L, Couraud S, Cortot AB, Touboul C, Lhomel C, Blay JY, Morère JF, Viguier J.

Bull Cancer. 2017 Mar;104(3):258-266. doi: 10.1016/j.bulcan.2016.12.002. Epub 2017 Jan 18. Review. French.

PMID:
28108012
18.

Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project.

Innominato PF, Komarzynski S, Mohammad-Djafari A, Arbaud A, Ulusakarya A, Bouchahda M, Haydar M, Bossevot-Desmaris R, Plessis V, Mocquery M, Bouchoucha D, Afshar M, Beau J, Karaboué A, Morère JF, Fursse J, Rovira Simon J, Levi F.

J Med Internet Res. 2016 Nov 25;18(11):e305.

19.

Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.

Bouchahda M, Boige V, Smith D, Karaboué A, Ducreux M, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Taieb J, Adam R, Lévi F; ARTBC International.

Eur J Cancer. 2016 Nov;68:163-172. doi: 10.1016/j.ejca.2016.09.011. Epub 2016 Oct 18.

PMID:
27768923
20.

Predictive Profile-Nomogram for Liver Resection for Breast Cancer Metastases: An Aggressive Approach with Promising Results.

Ruiz A, Wicherts DA, Sebagh M, Giacchetti S, Castro-Benitez C, van Hillegersberg R, Paule B, Castaing D, Morère JF, Adam R.

Ann Surg Oncol. 2017 Feb;24(2):535-545. doi: 10.1245/s10434-016-5522-7. Epub 2016 Aug 29.

PMID:
27573523
21.

[Renovascular safety of bevacizumab in breast cancer patients. The prognostic value of hypertension and proteinuria].

Launay-Vacher V, Janus N, Beuzeboc P, Daniel C, Ray-Coquard I, Selle F, Rey JB, Jouannaud C, Spano JP, Thery JC, Morere JF, Goldwasser F, Mir O, Oudard S, Scotté F, Dorent R, Ludwig L, Deray G, Gligorov J.

Bull Cancer. 2015 Nov;102(11):906-14. French.

PMID:
26603517
22.

Deposition of Ni nanoparticles onto porous supports using supercritical CO2: effect of the precursor and reduction methodology.

Morère J, Royuela S, Asensio G, Palomino P, Enciso E, Pando C, Cabañas A.

Philos Trans A Math Phys Eng Sci. 2015 Dec 28;373(2057). pii: 20150014. doi: 10.1098/rsta.2015.0014.

PMID:
26574525
23.

Repeat Hepatectomy for Breast Cancer Liver Metastases.

Ruiz A, Castro-Benitez C, Sebagh M, Giacchetti S, Castro-Santa E, Wicherts DA, van Hillegersberg R, Paule B, Castaing D, Morère JF, Adam R.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1057-66. doi: 10.1245/s10434-015-4785-8. Epub 2015 Aug 11.

PMID:
26259753
24.
25.

Lung cancer risks, beliefs and healthcare access among the underprivileged.

Morère JF, Viguier J, Touboul C, Pivot X, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S82-6. doi: 10.1097/CEJ.0000000000000143.

PMID:
26016793
26.

Social stratification, risk factor prevalence and cancer screening attendance.

Eisinger F, Viguier J, Touboul C, Coscas Y, Pivot X, Blay JY, Lhomel C, Morère JF.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S77-81. doi: 10.1097/CEJ.0000000000000144.

PMID:
26016792
27.

Breast cancer screening controversy: too much or not enough?

Pivot X, Viguier J, Touboul C, Morère JF, Blay JY, Coscas Y, Lhomel C, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S73-6. doi: 10.1097/CEJ.0000000000000145.

PMID:
26016791
28.

Cancer screening in France: third edition of the EDIFICE survey.

Viguier J, Morère JF, Touboul C, Coscas Y, Blay JY, Lhomel C, Pivot X, Eisinger F.

Eur J Cancer Prev. 2015 Jun;24 Suppl:S68-72. doi: 10.1097/CEJ.0000000000000146.

PMID:
26016790
29.

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.

Toledano A, Luporsi E, Morere JF, Scotté F, Laribi K, Barrière J, Huot-Marchand P, Duvillié L, Concas VH, Bugat R.

Support Care Cancer. 2016 Jan;24(1):67-75. doi: 10.1007/s00520-015-2728-3. Epub 2015 Apr 29.

PMID:
25921449
30.

Prostate cancer screening: contrasting trends.

Eisinger F, Morère JF, Touboul C, Pivot X, Coscas Y, Blay JY, Lhomel C, Viguier J.

Cancer Causes Control. 2015 Jun;26(6):949-52. doi: 10.1007/s10552-015-0573-9. Epub 2015 Mar 31.

PMID:
25822574
31.

Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).

Des Guetz G, Landre T, Westeel V, Milleron B, Vaylet F, Urban T, Barlesi F, Souquet PJ, Debieuvre D, Braun D, Fraboulet G, Monnet I, Uzzan B, Molinier O, Morin F, Moro-Sibilot D, Morère JF.

J Geriatr Oncol. 2015 May;6(3):233-40. doi: 10.1016/j.jgo.2015.02.002. Epub 2015 Feb 16.

PMID:
25698450
32.

Melanoma risk-takers: fathers and sons.

Eisinger F, Morère JF, Pivot X, Grange F, Lhomel C, Mortier L, Robert C, Saiag P, Sassolas B, Viguier J.

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:35-8. doi: 10.1111/jdv.12901.

PMID:
25639932
33.

Very late recurrence of Diethylstilbestrol - related clear cell carcinoma of the cervix: case report.

Adani-Ifè A, Goldschmidt E, Innominato P, Ulusakarya A, Errihani H, Bertheau P, Morère JF.

Gynecol Oncol Res Pract. 2015 Jul 17;2:3. doi: 10.1186/s40661-015-0010-5. eCollection 2015.

34.

ESMO 2014: new trends in precision medicine.

Morere JF, Innominato P.

Target Oncol. 2014 Dec;9(4):293-4. doi: 10.1007/s11523-014-0348-3. Epub 2014 Dec 13. No abstract available.

PMID:
25503266
35.

Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?

Allard MA, Saffroy R, de la Maisonneuve PB, Ricca L, Bosselut N, Hamelin J, Lecorche E, Bejarano MA, Innominato P, Sebagh M, Adam R, Morère JF, Lemoine A.

Target Oncol. 2015 Sep;10(3):415-21. doi: 10.1007/s11523-014-0346-5. Epub 2014 Nov 26.

PMID:
25420993
36.

Differential DNA methylation of the D4Z4 repeat in patients with FSHD and asymptomatic carriers.

Gaillard MC, Roche S, Dion C, Tasmadjian A, Bouget G, Salort-Campana E, Vovan C, Chaix C, Broucqsault N, Morere J, Puppo F, Bartoli M, Levy N, Bernard R, Attarian S, Nguyen K, Magdinier F.

Neurology. 2014 Aug 19;83(8):733-42. doi: 10.1212/WNL.0000000000000708. Epub 2014 Jul 16.

PMID:
25031281
37.

Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.

Soussan M, Cyrta J, Pouliquen C, Chouahnia K, Orlhac F, Martinod E, Eder V, Morère JF, Buvat I.

Radiology. 2014 Sep;272(3):875-84. doi: 10.1148/radiol.14132191. Epub 2014 Apr 23.

PMID:
24761836
38.

Accelerated senescence of cord blood endothelial progenitor cells in premature neonates is driven by SIRT1 decreased expression.

Vassallo PF, Simoncini S, Ligi I, Chateau AL, Bachelier R, Robert S, Morere J, Fernandez S, Guillet B, Marcelli M, Tellier E, Pascal A, Simeoni U, Anfosso F, Magdinier F, Dignat-George F, Sabatier F.

Blood. 2014 Mar 27;123(13):2116-26. doi: 10.1182/blood-2013-02-484956. Epub 2014 Feb 11.

PMID:
24518759
39.

Impact of physical activity on cancer-specific and overall survival of patients with colorectal cancer.

Des Guetz G, Uzzan B, Bouillet T, Nicolas P, Chouahnia K, Zelek L, Morere JF.

Gastroenterol Res Pract. 2013;2013:340851. doi: 10.1155/2013/340851. Epub 2013 Oct 3. Review.

40.

Case 198: solitary fibrous tumor of the liver.

Soussan M, Felden A, Cyrta J, Morère JF, Douard R, Wind P.

Radiology. 2013 Oct;269(1):304-8. doi: 10.1148/radiol.13121315. No abstract available.

PMID:
24062563
41.

ASCO 2013: from the rediscovery of old recipes to targeted oncology.

Morère JF.

Target Oncol. 2013 Sep;8(3):157-158. doi: 10.1007/s11523-013-0292-7. Epub 2013 Aug 23. No abstract available.

PMID:
23974863
42.

DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles.

Ferreboeuf M, Mariot V, Bessières B, Vasiljevic A, Attié-Bitach T, Collardeau S, Morere J, Roche S, Magdinier F, Robin-Ducellier J, Rameau P, Whalen S, Desnuelle C, Sacconi S, Mouly V, Butler-Browne G, Dumonceaux J.

Hum Mol Genet. 2014 Jan 1;23(1):171-81. doi: 10.1093/hmg/ddt409. Epub 2013 Aug 20.

43.

Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy.

Broucqsault N, Morere J, Gaillard MC, Dumonceaux J, Torrents J, Salort-Campana E, Maues De Paula A, Bartoli M, Fernandez C, Chesnais AL, Ferreboeuf M, Sarda L, Dufour H, Desnuelle C, Attarian S, Levy N, Nguyen K, Magdinier F, Roche S.

Hum Mol Genet. 2013 Oct 15;22(20):4206-14. doi: 10.1093/hmg/ddt272. Epub 2013 Jun 17.

PMID:
23777630
44.

Lung cancer: how to face the revolution?

Morère JF, Penault-Llorca F.

Target Oncol. 2013 Mar;8(1):1-2. doi: 10.1007/s11523-013-0265-x. Epub 2013 Feb 28. No abstract available.

PMID:
23443962
45.

Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial.

Gervais R, Robinet G, Clément-Duchêne C, Denis F, El Kouri C, Martin P, Chouaki N, Bourayou N, Morère JF.

Lung Cancer. 2013 May;80(2):185-90. doi: 10.1016/j.lungcan.2013.01.008. Epub 2013 Feb 21.

PMID:
23434351
46.

[Support for children of parents suffering from cancer].

Liu M, Morère JF, Vernois S, Casassus P, Baubet T.

Soins Pediatr Pueric. 2013 Jan-Feb;(270):42-5. French.

PMID:
23379071
47.

Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy.

Soussan M, Chouahnia K, Maisonobe JA, Boubaya M, Eder V, Morère JF, Buvat I.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):668-76. doi: 10.1007/s00259-012-2321-7. Epub 2013 Jan 11.

PMID:
23306807
48.

Oncology in 2012: from personalized medicine to precision medicine.

Morere JF.

Target Oncol. 2012 Dec;7(4):211-2. doi: 10.1007/s11523-012-0238-5. Epub 2012 Nov 22. No abstract available.

PMID:
23179557
49.

The rim sign: FDG-PET/CT pattern of pulmonary infarction.

Soussan M, Rust E, Pop G, Morère JF, Brillet PY, Eder V.

Insights Imaging. 2012 Dec;3(6):629-33. doi: 10.1007/s13244-012-0189-5. Epub 2012 Aug 18.

50.

Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.

Duruisseaux M, Baudrin L, Quoix E, Wislez M, Moro-Sibilot D, Coëtmeur D, Monnet I, Mourlanette P, Morère JF, Soria JC, Westeel V, Morin F, Cadranel J.

J Thorac Oncol. 2012 Sep;7(9):1423-31.

Supplemental Content

Loading ...
Support Center